Additionally, we observed that all SGLT2 inhibitors, with the exception of dapagliflozin were associated with increased risks of mycotic genital infections, and that canagliflozin was associated with an increased risk of lower limb amputation in in the patients with DM. Here, SLC5A2 is linked to diabetes mellitus.